์ฝ˜ํ…์ธ ๋กœ ๊ฑด๋„ˆ๋›ฐ๊ธฐ
Merck

F6777

Flecainide acetate salt

≥98% (HPLC), powder, sodium channel blocker

๋™์˜์–ด(๋“ค):

N-(2-Piperidylmethyl)-2,5-bis-(2,2,2-trifluoroethoxy)benzamide acetate salt

์กฐ์ง ๋ฐ ๊ณ„์•ฝ ๊ฐ€๊ฒฉ์„ ๋ณด๋ ค๋ฉด ๋กœ๊ทธ์ธ๋ฅผ ํด๋ฆญํ•ฉ๋‹ˆ๋‹ค.

ํฌ๊ธฐ ์„ ํƒ

๋ณด๊ธฐ ๋ณ€๊ฒฝ

์ œํ’ˆ์ •๋ณด (DICE ๋ฐฐ์†ก ์‹œ ๋น„์šฉ ๋ณ„๋„)

์‹คํ—˜์‹(Hill ํ‘œ๊ธฐ๋ฒ•):
C17H20F6N2O3 ยท C2H4O2
CAS ๋ฒˆํ˜ธ:
Molecular Weight:
474.39
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
258-997-5
MDL number:
๊ธฐ์ˆ  ์„œ๋น„์Šค
๋„์›€์ด ํ•„์š”ํ•˜์‹ ๊ฐ€์š”? ์ €ํฌ ์ˆ™๋ จ๋œ ๊ณผํ•™์ž ํŒ€์ด ๋„์™€๋“œ๋ฆฌ๊ฒ ์Šต๋‹ˆ๋‹ค.
๋„์›€ ๋ฌธ์˜


์ œํ’ˆ ์ด๋ฆ„

Flecainide acetate salt,

Quality Segment

originator

Medicis

storage temp.

2-8ยฐC

SMILES string

CC(O)=O.FC(F)(F)COc1ccc(OCC(F)(F)F)c(c1)C(=O)NCC2CCCCN2

InChI

1S/C17H20F6N2O3.C2H4O2/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11;1-2(3)4/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26);1H3,(H,3,4)

InChI key

RKXNZRPQSOPPRN-UHFFFAOYSA-N

Gene Information

human ... SCN5A(6331)

Biochem/physiol Actions

Class IC antiarrhythmic agent; sodium channel blocker

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Medicis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.


pictograms

Health hazardExclamation mark

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

์ €์žฅ ๋“ฑ๊ธ‰

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable



๊ฐ€์žฅ ์ตœ์‹  ๋ฒ„์ „ ์ค‘ ํ•˜๋‚˜๋ฅผ ์„ ํƒํ•˜์„ธ์š”:

์‹œํ—˜ ์„ฑ์ ์„œ(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our ๋ฌธ์„œ section.

๋„์›€์ด ํ•„์š”ํ•˜์‹œ๋ฉด ์—ฐ๋ฝํ•˜์„ธ์š”. ๊ณ ๊ฐ ์ง€์› ๋ถ€์„œ

์ด ์ œํ’ˆ์„ ์ด๋ฏธ ๊ฐ€์ง€๊ณ  ๊ณ„์‹ญ๋‹ˆ๊นŒ?

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ์—์„œ ์ตœ๊ทผ์— ๊ตฌ๋งคํ•œ ์ œํ’ˆ์— ๋Œ€ํ•œ ๋ฌธ์„œ๋ฅผ ์ฐพ์•„๋ณด์„ธ์š”.

๋ฌธ์„œ ๋ผ์ด๋ธŒ๋Ÿฌ๋ฆฌ ๋ฐฉ๋ฌธ